• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

优化用于黏液性上皮性卵巢癌的Ventana显色双重原位杂交技术

Optimizing Ventana chromogenic dual in-situ hybridization for mucinous epithelial ovarian cancer.

作者信息

Li Xinyun, Chew Sung-Hock, Chay Wen-Yee, Lim-Tan Soo-Kim, Goh Liang-Kee

机构信息

Cancer & Stem Cell Biology, Duke-National University of Singapore, Singapore, Singapore.

出版信息

BMC Res Notes. 2013 Dec 28;6:562. doi: 10.1186/1756-0500-6-562.

DOI:10.1186/1756-0500-6-562
PMID:24373486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3892083/
Abstract

BACKGROUND

Dual in-situ hybridization (DISH) assay is a relatively new assay for evaluating Human Epidermal Growth Factor Receptor 2 (HER2) genomic amplification. Optimization protocol for the assay is not yet well established, especially for archival tissues. Although there is a recommended nominal protocol, it is not suited for formalin-fixed and paraffin-embedded (FFPE) samples that were archived for long periods.

FINDINGS

In a study on local population of mucinous epithelial ovarian cancer, we developed a series of optimization protocols based on the age of samples to improve success of the DISH assay. A decision workflow was generated to facilitate individualization of further optimization protocols. The optimizations were evaluated on 92 whole tissue sections of FFPE mucinous ovarian tumors dating from 1990 to 2011. Overall, 79 samples were successfully assayed for DISH using the series of optimization protocols. We found samples older than 1 year required further optimization beyond the nominal protocol recommended. Thirteen samples were not further assayed after first DISH assay due to inadequately preserved nuclear morphology with no ISH signals throughout the tissue section.

CONCLUSION

The study revealed age of samples and storage conditions were major factors in successful DISH assays. Samples that were ten years or less in age, and archived in-house were successfully optimized, whereas older samples, which were also archived off-site, have a higher frequency of unsuccessful optimizations. The study provides practical and important guidelines for the new DISH assay which can facilitate successful HER2 evaluation in ovarian cancers and possibly other cancers as well.

摘要

背景

双重原位杂交(DISH)检测是一种用于评估人表皮生长因子受体2(HER2)基因扩增的相对较新的检测方法。该检测方法的优化方案尚未完全确立,尤其是对于存档组织。尽管有推荐的标准方案,但它不适用于长期存档的福尔马林固定石蜡包埋(FFPE)样本。

研究结果

在一项针对黏液性上皮性卵巢癌当地人群的研究中,我们根据样本的年龄制定了一系列优化方案,以提高DISH检测的成功率。生成了一个决策工作流程,以促进进一步优化方案的个性化。对1990年至2011年的92个FFPE黏液性卵巢肿瘤全组织切片进行了优化评估。总体而言,使用该系列优化方案成功对79个样本进行了DISH检测。我们发现,超过1年的样本需要在推荐的标准方案之外进行进一步优化。13个样本在首次DISH检测后未进一步检测,原因是核形态保存不佳,整个组织切片均无ISH信号。

结论

该研究表明,样本年龄和储存条件是DISH检测成功的主要因素。年龄在10年及以下且在内部存档的样本成功得到优化,而年龄较大且在外部存档的样本优化失败的频率较高。该研究为新的DISH检测提供了实用且重要的指导方针,有助于在卵巢癌以及可能的其他癌症中成功评估HER2。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dc4/3892083/ff2bfe6555fb/1756-0500-6-562-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dc4/3892083/b1899116ae30/1756-0500-6-562-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dc4/3892083/4526fa061278/1756-0500-6-562-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dc4/3892083/ff2bfe6555fb/1756-0500-6-562-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dc4/3892083/b1899116ae30/1756-0500-6-562-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dc4/3892083/4526fa061278/1756-0500-6-562-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dc4/3892083/ff2bfe6555fb/1756-0500-6-562-3.jpg

相似文献

1
Optimizing Ventana chromogenic dual in-situ hybridization for mucinous epithelial ovarian cancer.优化用于黏液性上皮性卵巢癌的Ventana显色双重原位杂交技术
BMC Res Notes. 2013 Dec 28;6:562. doi: 10.1186/1756-0500-6-562.
2
A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.一种用于人表皮生长因子受体 2(HER2)的基因-蛋白检测方法:在福尔马林固定、石蜡包埋的乳腺癌组织切片中,对 HER2 蛋白、HER2 基因和 17 号染色体着丝粒(CEN17)进行明场三色可视化。
Diagn Pathol. 2012 May 30;7:60. doi: 10.1186/1746-1596-7-60.
3
Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.采用 INFORM HER2 双色原位杂交技术对人表皮生长因子受体 2 检测进行验证和工作流程优化。
Hum Pathol. 2013 Nov;44(11):2590-6. doi: 10.1016/j.humpath.2013.07.005. Epub 2013 Sep 25.
4
Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.乳腺癌细胞块的明场HER2双原位杂交(DISH)检测:与组织切片的比较研究
Breast Cancer. 2016 Nov;23(6):917-921. doi: 10.1007/s12282-015-0664-1. Epub 2016 Jan 8.
5
HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.应用亮场双色荧光原位杂交技术检测复发性和转移性乳腺癌细胞块中的 HER2 状态。
Cancer Cytopathol. 2019 Nov;127(11):684-690. doi: 10.1002/cncy.22184. Epub 2019 Sep 22.
6
Optimization of the Affymetrix GeneChip Mapping 10K 2.0 Assay for routine clinical use on formalin-fixed paraffin-embedded tissues.优化Affymetrix基因芯片Mapping 10K 2.0检测方法,以便在福尔马林固定石蜡包埋组织上进行常规临床应用。
Diagn Mol Pathol. 2008 Mar;17(1):3-13. doi: 10.1097/PDM.0b013e31815aca30.
7
Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.采用免疫组织化学(IHC)和荧光原位杂交(FISH)技术评估黏液性上皮性卵巢癌中的HER2状态:ToGA活检法与ToGA手术标本法的全面比较
PLoS One. 2015 Nov 13;10(11):e0142135. doi: 10.1371/journal.pone.0142135. eCollection 2015.
8
Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.双色 HER2/17 染色体原位杂交可准确评估卵巢肿瘤的 HER2 基因组状态。
J Clin Pathol. 2011 Dec;64(12):1097-101. doi: 10.1136/jclinpath-2011-200082. Epub 2011 Sep 6.
9
HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.用于乳腺癌细胞块的HER 2免疫组织化学检测方法与用于组织学标本的方法相同。
Diagn Cytopathol. 2016 Apr;44(4):274-9. doi: 10.1002/dc.23433. Epub 2016 Jan 22.
10
Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors.采用显色原位杂交技术检测卵巢肿瘤中HER-2和EGFR基因扩增情况。
Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):69-74. doi: 10.1097/PAI.0b013e3181af7d3f.

引用本文的文献

1
Chromogenic In Situ Hybridization (CISH) as a Method for Detection of C-Myc Amplification in Formalin-Fixed Paraffin-Embedded Tumor Tissue: An Update.显色原位杂交(CISH)作为检测福尔马林固定石蜡包埋肿瘤组织中 C-Myc 扩增的方法:更新。
Methods Mol Biol. 2021;2318:313-320. doi: 10.1007/978-1-0716-1476-1_17.

本文引用的文献

1
HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.在一个大型亚洲罕见黏液性卵巢癌队列中,HER2 扩增与临床病理特征。
PLoS One. 2013 Apr 19;8(4):e61565. doi: 10.1371/journal.pone.0061565. Print 2013.
2
Histotype-specific copy-number alterations in ovarian cancer.卵巢癌的组织型特异性拷贝数改变。
BMC Med Genomics. 2012 Oct 18;5:47. doi: 10.1186/1755-8794-5-47.
3
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
黏液性卵巢肿瘤的分子特征支持分层治疗方法,其中 19%的癌可针对 HER2 进行靶向治疗。
J Pathol. 2013 Jan;229(1):111-20. doi: 10.1002/path.4088.
4
A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.一种用于人表皮生长因子受体 2(HER2)的基因-蛋白检测方法:在福尔马林固定、石蜡包埋的乳腺癌组织切片中,对 HER2 蛋白、HER2 基因和 17 号染色体着丝粒(CEN17)进行明场三色可视化。
Diagn Pathol. 2012 May 30;7:60. doi: 10.1186/1746-1596-7-60.
5
The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.冷缺血时间对浸润性乳腺癌中雌激素受体、孕激素受体和 HER2 表达的免疫组织化学评估的影响。
Mod Pathol. 2012 Aug;25(8):1098-105. doi: 10.1038/modpathol.2012.59. Epub 2012 Mar 30.
6
Pathology of primary and metastatic mucinous ovarian neoplasms.原发性和转移性黏液性卵巢肿瘤的病理学。
J Clin Pathol. 2012 Jul;65(7):591-5. doi: 10.1136/jclinpath-2011-200162. Epub 2011 Nov 10.
7
Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.双色 HER2/17 染色体原位杂交可准确评估卵巢肿瘤的 HER2 基因组状态。
J Clin Pathol. 2011 Dec;64(12):1097-101. doi: 10.1136/jclinpath-2011-200082. Epub 2011 Sep 6.
8
Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer.双色银增强原位杂交检测乳腺癌 HER2 基因扩增。
Mod Pathol. 2011 Jun;24(6):794-800. doi: 10.1038/modpathol.2011.9. Epub 2011 Feb 11.
9
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.走出黑暗,步入光明:亮场原位杂交在乳腺癌中 ERBB2(HER2)状态描绘中的应用。
J Clin Pathol. 2010 Mar;63(3):210-9. doi: 10.1136/jcp.2009.062760.
10
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.HER2 过表达和扩增存在于一部分卵巢黏液性癌中,并且可以用曲妥珠单抗治疗进行靶向治疗。
BMC Cancer. 2009 Dec 10;9:433. doi: 10.1186/1471-2407-9-433.